Amended Current Report Filing (8-k/a)
16 Novembre 2020 - 10:52PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 27, 2020
CEREVEL THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-39311
|
|
98-1533670
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
131 Dartmouth Street, Suite 502
Boston, MA 02116
(Address
of principal executive offices, including zip code)
(844) 304-2048
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, par value $0.0001 per share
|
|
CERE
|
|
The Nasdaq Capital Market
|
Warrants to purchase one share of common stock at an exercise price of $11.50
|
|
CEREW
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Introductory Note
This Amendment No. 1 on Form 8-K/A (Amendment No. 1) amends the Current Report on Form 8-K of Cerevel Therapeutics Holdings, Inc., a Delaware corporation (the Company), filed on November 2, 2020 (the Original Report), in which the Company reported, among other events, the
completion of the Business Combination (as defined in the Original Report) between the Company and Cerevel Therapeutics, Inc. (Old Cerevel).
This Amendment No. 1 is being filed in order to include (a) the unaudited pro forma condensed combined financial information for the Company as of
and for the nine months ended September 30, 2020, (b) the Managements Discussion and Analysis of Financial Condition and Results of Operations of Old Cerevel for the three and nine months ended September 30, 2020 and 2019 and
(c) the unaudited condensed consolidated financial statements of Old Cerevel as of September 30, 2020 and for the three and nine months ended September 30, 2020 and 2019.
This Amendment No. 1 does not amend any other item of the Original Report or purport to provide an update or a discussion of any developments at the
Company or its subsidiaries subsequent to the filing date of the Original Report, except as indicated below under Item 9.01. The information previously reported in or filed with the Original Report is hereby incorporated by reference to this
Amendment No. 1.
Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements.
The unaudited condensed consolidated
financial statements of Old Cerevel as of September 30, 2020 and for the three and nine months ended September 30, 2020 and 2019, and the related notes thereto are attached as Exhibit 99.3 and are incorporated herein by reference. Also
included as Exhibit 99.2 and incorporated herein by reference is the Managements Discussion and Analysis of Financial Condition and Results of Operations of Old Cerevel for the three and nine months ended September 30, 2020 and 2019.
(b) Pro Forma Financial Information.
Certain unaudited pro
forma condensed combined financial information for the Company as of and for the nine months ended September 30, 2020 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CEREVEL THERAPEUTICS HOLDINGS, INC.
|
|
|
|
|
Date: November 16, 2020
|
|
|
|
By:
|
|
/s/ Kathy Yi
|
|
|
|
|
|
|
Kathy Yi
|
|
|
|
|
|
|
Chief Financial Officer
|
ARYA Sciences Acquisitio... (NASDAQ:ARYBU)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
ARYA Sciences Acquisitio... (NASDAQ:ARYBU)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
Real-Time news about ARYA Sciences Acquisition Corporation II (NASDAQ): 0 recent articles
Plus d'articles sur Cerevel Therapeutics Holdings, Inc.